These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28652421)

  • 1. Clinical Significance of
    Katayama Y; Oshima T; Sakamaki K; Aoyama T; Sato T; Masudo K; Shiozawa M; Yoshikawa T; Rino Y; Imada T; Masuda M
    In Vivo; 2017; 31(4):565-571. PubMed ID: 28652421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Tensin 4 Gene Expression in Patients with Gastric Cancer.
    Sawazaki S; Oshima T; Sakamaki K; Aoyama T; Sato T; Shiozawa M; Yoshikawa T; Rino Y; Imada T; Masuda M
    In Vivo; 2017; 31(6):1065-1071. PubMed ID: 29102927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of INHBA gene expression to outcomes in gastric cancer after curative surgery.
    Oshima T; Yoshihara K; Aoyama T; Hasegawa S; Sato T; Yamamoto N; Akito N; Shiozawa M; Yoshikawa T; Numata K; Rino Y; Kunisaki C; Tanaka K; Akaike M; Imada T; Masuda M
    Anticancer Res; 2014 May; 34(5):2303-9. PubMed ID: 24778035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.
    Numata K; Oshima T; Sakamaki K; Yoshihara K; Aoyama T; Hayashi T; Yamada T; Sato T; Cho H; Shiozawa M; Yoshikawa T; Rino Y; Kunisaki C; Akaike M; Imada T; Masuda M
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):415-22. PubMed ID: 26337161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.
    Maezawa Y; Sakamaki K; Oue N; Kimura Y; Hashimoto I; Hara K; Kano K; Aoyama T; Hiroshima Y; Yamada T; Yamamoto N; Ogata T; Ito H; Cho H; Shiozawa M; Yoshikawa T; Morinaga S; Rino Y; Yasui W; Masuda M; Miyagi Y; Oshima T
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):75-86. PubMed ID: 31754833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
    Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.
    Hashimoto I; Oue N; Kimura Y; Hiroshima Y; Hara K; Maezawa Y; Kano K; Fujikawa H; Aoyama T; Numata M; Yamada T; Tamagawa H; Yamamoto N; Ogata T; Shiozawa M; Morinaga S; Rino Y; Yasui W; Masuda M; Miyagi Y; Oshima T
    Anticancer Res; 2020 Oct; 40(10):5815-5821. PubMed ID: 32988910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
    Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
    BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
    Kim JY; Shin E; Kim JW; Lee HS; Lee DW; Kim SH; Lee JO; Kim YJ; Kim JH; Bang SM; Ahn SH; Park DJ; Lee JS; Lee JS; Kim HH; Lee KW
    PLoS One; 2015; 10(3):e0120324. PubMed ID: 25793299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of
    Hatori S; Sakamaki K; Yokohori T; Kimura Y; Hiroshima Y; Hashimoto I; Komori K; Watanabe H; Kano K; Fujikawa H; Aoyama T; Numata M; Yamada T; Tamagawa H; Yamamoto N; Ogata T; Shizawa M; Yukawa N; Morinaga S; Rino Y; Masuda M; Saeki H; Miyagi Y; Oshima T
    Anticancer Res; 2021 Jul; 41(7):3583-3588. PubMed ID: 34230154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?
    Fujitani K; Kurokawa Y; Takeno A; Endoh S; Ohmori T; Fujita J; Yamasaki M; Takiguchi S; Mori M; Doki Y;
    Gastric Cancer; 2018 May; 21(3):446-452. PubMed ID: 28965205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
    Cho JH; Lim JY; Cho JY
    PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
    Mita K; Ito H; Ota E; Takahashi K; Hashimoto M; Asakawa H; Hayashi T; Fujino K
    Anticancer Res; 2017 Mar; 37(3):1329-1333. PubMed ID: 28314299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis.
    Nakamura K; Hatakeyama K; Furukawa K; Fujiya K; Kamiya S; Hikage M; Tanizawa Y; Bando E; Ohshima K; Urakami K; Machida N; Yasui H; Yamaguchi K; Terashima M
    Gastric Cancer; 2020 Jul; 23(4):648-658. PubMed ID: 32185558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
    Kim SG; Hwang SH
    World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
    Omura T; Shimada Y; Nagata T; Okumura T; Fukuoka J; Yamagishi F; Tajika S; Nakajima S; Kawabe A; Tsukada K
    Oncol Rep; 2014 Feb; 31(2):613-8. PubMed ID: 24317477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.